Silencing of cystatin SN abrogates cancer progression and stem cell properties in papillary thyroid carcinoma

Papillary thyroid carcinoma (PTC) accounts for approximately 80% of total thyroid cancers worldwide. Although the prognosis for early‐stage PTC is favorable, the 5‐year survival rate of patients with late‐stage PTC is still very poor. Cystatin SN (cystatin 1, CST1) facilitates the progression of mul...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Jiaojiao, Wang, Xiaorong, Gao, Junxi, Song, Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8329778/
https://www.ncbi.nlm.nih.gov/pubmed/34102026
http://dx.doi.org/10.1002/2211-5463.13221

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8329778/
https://www.ncbi.nlm.nih.gov/pubmed/34102026
http://dx.doi.org/10.1002/2211-5463.13221

Ejemplares similares